Next-Generation Glycemic Control Therapeutics

Chart_Collage_160   Published August 2015  •  Catalog no. GCT494R  •  Price US $3,850

As the number of patients diagnosed with diabetes continues to climb worldwide, drug developers and researchers are attempting for find more effective ways to control glucose levels, particularly for Type 2 diabetics. These efforts have led to a growing list of GLP-1 agonists and DPP-4 inhibitors that have been approved or are in late stage clinical development. New medicines based on novel therapeutic moieties and potentially unique benefits are attracting attention and research investment. The result is an evolving therapeutic landscape that is providing clinicians and patients with new ways to manage their diabetes. For market participants, product positioning and prescriber training will become increasingly important as competitive threats remain fluid.

 Bar_Graph  Next-Generation Glycemic Control Therapeutics Report Prospectus (Download PDF Report Brochure)

Blue document    Next-Generation Glycemic Control Therapeutics Report Order Form (Download PDF Report Order Form)



•    What therapeutic drugs are currently marketed for glycemic control, how are they administered, who markets them, and what is the size of the global market?
•    What are the important factors in patient self-administration of glycemic drugs, what are the current prescribing trends, and what are the key factors influencing demand?
•    What are the regional factors affecting market size and demand?
•    What are the new classes of drugs that are entering the market for treating diabetes, what is their market share and what are their growth prospects?
•    What drugs are expected to enter the market in the next five years, and what will be their probable impact on the overall market?
•    What are the significant economic, technology, and regulatory factors affecting the market for glycemic control therapeutics?


Summary of Contents

Executive SummaryThe Market Opportunity
Glycemic Control Market Dynamics
Market Segments
What’s Driving the Market?
Shifting Demographics
Therapeutic Demand Drivers
Competitive Landscape
Risk FactorsApproved Next-Generation Therapeutics
Inhaled Insulin
GLP-1 Agonists
Amylin Analogs
DPP-4 Inhibitors
Sodium-Glucose Co-transporter 2 (SGLT2) InhibitorsDevelopment-stage Glycemic Control Products
Inhaled Insulin
GLP-1 Agonists
DPP-4 Inhibitors
SGLT2 Inhibitors
Dual Therapy Drugs
New MOAs
Glucagon Receptor Antagonist

Market Data and Forecasts

Market Factors
Regulatory Issues
Patient Compliance and Ease of Use
Healthcare Economics
Regional Market Factors

Company Profiles